Marconi Medical Systems Gets FDA Clearance for Large-Bore Oncology CT Scanner

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

CLEVELAND-Marconi Medical Systems has received 510k clearance from the FDA to market its new ACQSIM CT scanner that addresses the special needs of oncology CT simulation and planning.

CLEVELAND—Marconi Medical Systems has received 510k clearance from the FDA to market its new ACQSIM CT scanner that addresses the special needs of oncology CT simulation and planning.

The ACQSIM CT scanner is designed with an 85-cm large bore, to simplify planning difficult cases, including breast, Hodgkin’s lymphoma, and large patients.

The acQsim system includes a high-precision localization and marking system and a virtual simulator that yield digitally composited and/or reconstructed radiographs that exceed the requirements of conformal and high-precision radiotherapy delivery, the company said.

The footprint of the new scanner is the same as that of standard 70-cm diagnostic CTs and is designed to fit into rooms that currently house a conventional simulator or CT scanner.

Several sites will be installed in 2000, the company said, with general product release scheduled for the spring of 2001.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content